Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles

Introduction: With the advancement in the field of medical colloids and interfacial sciences, the life expectancy has been greatly improved. In addition, changes in the human lifestyle resulted in development of various organic and functional disorders. Central nervous system (CNS) disorders are most prevalent and increasing among population worldwide. The neurological disorders are multi-systemic and difficult to treat as portal entry to brain is restricted on account of its anatomical and physiological barrier. Areas covered: The present review discusses the limitations to CNS drug delivery, and the various approaches to bypass the blood brain barrier (BBB), focusing on the potential use of solid lipid nanoparticles (SLN) for drug targeting to brain. The methods currently in use for SLN production, physicochemical characterization and critical issues related to the formulation development suitable for targeting brain are also discussed. Expert opinion: The potential advantages of the use of SLN over polymeric nanoparticles are due to their lower cytotoxicity, higher drug loading capacity and scalability. In addition, their production is cost effective and the systems provide a drug release in a controlled manner up to several weeks. Drug targeting potential of SLN can be enhanced by attaching ligands to their surface.

[1]  Silke Krol,et al.  Challenges in drug delivery to the brain: nature is against us. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Luciana Romão,et al.  Glioblastoma: therapeutic challenges, what lies ahead. , 2012, Biochimica et biophysica acta.

[3]  A. Palmer,et al.  Translational CNS medicines research. , 2012, Drug discovery today.

[4]  J. Vishwanatha,et al.  Combinatorial nanoparticles for cancer diagnosis and therapy. , 2012, Current medicinal chemistry.

[5]  Svetlana Gelperina,et al.  Transport of drugs across the blood-brain barrier by nanoparticles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[6]  E. Souto,et al.  Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. , 2012, International journal of pharmaceutics.

[7]  H. Potschka.  Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport. , 2012, Advanced drug delivery reviews.

[8]  I. Elkin,et al.  Drug-loaded nanocarriers: passive targeting and crossing of biological barriers. , 2012, Current medicinal chemistry.

[9]  Yu Liu,et al.  Recent advances in brain tumor-targeted nano-drug delivery systems , 2012, Expert opinion on drug delivery.

[10]  X. Wu,et al.  Nanotechnological advances for the delivery of CNS therapeutics. , 2012, Advanced drug delivery reviews.

[11]  M. Gallarate,et al.  Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery , 2012, Expert opinion on drug delivery.

[12]  S. Fatemi,et al.  Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size. , 2012, International journal of pharmaceutics.

[13]  R. Fahmy,et al.  Evaluation of hypericin-loaded solid lipid nanoparticles: Physicochemical properties, photostability and phototoxicity , 2012, Pharmaceutical development and technology.

[14]  Kofi-Buaku Atsina,et al.  Novel Delivery Strategies for Glioblastoma , 2012, Cancer journal.

[15]  R. Braga,et al.  Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  E. Souto,et al.  Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. , 2011, Colloids and surfaces. B, Biointerfaces.

[17]  M. H. Santana,et al.  Polymorphism, crystallinity and hydrophilic-lipophilic balance of stearic acid and stearic acid-capric/caprylic triglyceride matrices for production of stable nanoparticles. , 2011, Colloids and surfaces. B, Biointerfaces.

[18]  M. E. Morales,et al.  Lipid-based drug delivery systems for cancer treatment. , 2011, Current drug targets.

[19]  H. Hayashi.  Lipid metabolism and glial lipoproteins in the central nervous system. , 2011, Biological & pharmaceutical bulletin.

[20]  T. Dutta,et al.  Development, characterization and in vitro assessement of stearylamine-based lipid nanoparticles of paclitaxel. , 2011, Pharmazie.

[21]  Etienne Sibille,et al.  Brain molecular aging, promotion of neurological disease and modulation by Sirtuin5 longevity gene polymorphism , 2011, Neurobiology of Disease.

[22]  Etienne Sibille,et al.  Between destiny and disease: Genetics and molecular pathways of human central nervous system aging , 2011, Progress in Neurobiology.

[23]  C. Fernandes,et al.  Nano-interventions for neurodegenerative disorders. , 2010, Pharmacological research.

[24]  W. Pardridge,et al.  Alzheimer's disease drug development and the problem of the blood-brain barrier , 2009, Alzheimer's & Dementia.

[25]  F. Mollinedo,et al.  Lipid nanomedicines for anticancer drug therapy. , 2009, Journal of biomedical nanotechnology.

[26]  Mansoor M Amiji,et al.  Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases , 2009, Expert opinion on drug delivery.

[27]  Yaping Li,et al.  The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases. , 2008, Biomaterials.

[28]  R. Bhandari,et al.  Potential of solid lipid nanoparticles in brain targeting. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[29]  R. Doijad,et al.  Formulation and Targeting Efficiency of Cisplatin Engineered Solid Lipid Nanoparticles , 2008, Indian journal of pharmaceutical sciences.

[30]  Y. Kuo,et al.  Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. , 2007, International journal of pharmaceutics.

[31]  Maxime Culot,et al.  Modelling of the blood–brain barrier in drug discovery and development , 2007, Nature Reviews Drug Discovery.

[32]  M. Ricci,et al.  Solid lipid nanoparticles for targeted brain drug delivery. , 2007, Advanced drug delivery reviews.

[33]  Sanjay K. Jain,et al.  Transferrin‐conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain , 2007, The Journal of pharmacy and pharmacology.

[34]  J. Bruce,et al.  Targeting the Brain , 2007, Neurocritical care.

[35]  H. Newton,et al.  Advances in strategies to improve drug delivery to brain tumors , 2006, Expert review of neurotherapeutics.

[36]  M. Schubert,et al.  Structural investigations on lipid nanoparticles containing high amounts of lecithin. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[37]  R. Müller,et al.  Polymorphic behaviour of Compritol®888 ATO as bulk lipid and as SLN and NLC , 2006, Journal of microencapsulation.

[38]  V. Venkateswarlu,et al.  Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration , 2006, Journal of drug targeting.

[39]  M. Gumbleton,et al.  Endocytosis at the blood–brain barrier: From basic understanding to drug delivery strategies , 2006, Journal of drug targeting.

[40]  L. Rizza,et al.  Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. , 2005, International journal of pharmaceutics.

[41]  V. Venkateswarlu,et al.  Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[42]  R. Murthy,et al.  Etoposide-loaded nanoparticles made from glyceride lipids: Formulation, characterization, in vitro drug release, and stability evaluation , 2005, AAPS PharmSciTech.

[43]  M. Schubert,et al.  Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[44]  R. Sharma,et al.  Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[45]  R. Müller,et al.  Physicochemical investigations on the structure of drug-free and drug-loaded solid lipid nanoparticles (SLN) by means of DSC and 1H NMR. , 2005, Die Pharmazie.

[46]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[47]  J. Gee,et al.  Astrocytes: regulation of brain homeostasis via apolipoprotein E. , 2005, The international journal of biochemistry & cell biology.

[48]  W. Pardridge.  Molecular biology of the blood-brain barrier , 2005, Methods in molecular medicine.

[49]  R. Müller,et al.  Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns , 2005, Journal of drug targeting.

[50]  R. Müller,et al.  Comparative study between the viscoelastic behaviors of different lipid nanoparticle formulations. , 2005, Journal of the Society of Cosmetic Chemists.

[51]  Paul R. Lockman,et al.  Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability , 2004, Journal of drug targeting.

[52]  Y. Sugiyama,et al.  Drug transfer in the choroid plexus. Multiplicity and substrate specificities of transporters , 2004 .

[53]  T. Unruh,et al.  Investigation on the flow behavior of dispersions of solid triglyceride nanoparticles. , 2004, International journal of pharmaceutics.

[54]  D. Begley.  Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. , 2004, Pharmacology & therapeutics.

[55]  R. Mumper,et al.  Paclitaxel nanoparticles for the potential treatment of brain tumors. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[56]  H. Benson,et al.  Drug delivery across the blood-brain barrier. , 2004, Current drug delivery.

[57]  N. Joan Abbott,et al.  Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology , 2004, Neurochemistry International.

[58]  R. Müller,et al.  Solid lipid nanoparticles for parenteral drug delivery. , 2004, Advanced drug delivery reviews.

[59]  R. Müller,et al.  Influence of surfactants on the physical stability of solid lipid nanoparticle (SLN) formulations. , 2004, Die Pharmazie.

[60]  R. Müller,et al.  Structural Characterization of Q10-Loaded Solid Lipid Nanoparticles by NMR Spectroscopy , 2004, Pharmaceutical Research.

[61]  R. Müller,et al.  SolEmuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs. , 2004, International journal of pharmaceutics.

[62]  Russell J Mumper,et al.  Brain uptake of thiamine-coated nanoparticles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[63]  R. Mumper,et al.  In Situ Blood–Brain Barrier Transport of Nanoparticles , 2003, Pharmaceutical Research.

[64]  D. E. Clark.  In silico prediction of blood-brain barrier permeation. , 2003, Drug discovery today.

[65]  K. Mäder,et al.  Physicochemical Investigations on Solid Lipid Nanoparticles and on Oil-Loaded Solid Lipid Nanoparticles: A Nuclear Magnetic Resonance and Electron Spin Resonance Study , 2003, Pharmaceutical Research.

[66]  H. Bunjes,et al.  Influence of emulsifiers on the crystallization of solid lipid nanoparticles. , 2003, Journal of pharmaceutical sciences.

[67]  Paul R. Lockman,et al.  In Vivo and in Vitro Assessment of Baseline Blood-Brain Barrier Parameters in the Presence of Novel Nanoparticles , 2003, Pharmaceutical Research.

[68]  C. Xie,et al.  The production and characteristics of solid lipid nanoparticles (SLNs). , 2003, Biomaterials.

[69]  J. Kristl,et al.  Interactions of solid lipid nanoparticles with model membranes and leukocytes studied by EPR. , 2003, International journal of pharmaceutics.

[70]  P. Couvreur,et al.  Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. , 2003, Advanced drug delivery reviews.

[71]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[72]  W. Pardridge.  Blood-brain barrier drug targeting: the future of brain drug development. , 2003, Molecular interventions.

[73]  A. Sbarbati,et al.  In Vitro and In Vivo Study of Solid Lipid Nanoparticles Loaded with Superparamagnetic Iron Oxide , 2003, Journal of drug targeting.

[74]  W. Pardridge,et al.  Drug and Gene Delivery to the Brain The Vascular Route , 2002, Neuron.

[75]  Xun Sun,et al.  Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[76]  R. Müller,et al.  Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. , 2002, Advanced drug delivery reviews.

[77]  Hartwig Wolburg,et al.  Tight junctions of the blood-brain barrier: development, composition and regulation. , 2002, Vascular pharmacology.

[78]  N. Abbott.  Astrocyte–endothelial interactions and blood–brain barrier permeability , 2002, Journal of anatomy.

[79]  R. Cavalli,et al.  Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. , 2002, Journal of pharmaceutical sciences.

[80]  R. Müller,et al.  Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)--effect of surfactants, storage time and crystallinity. , 2002, International journal of pharmaceutics.

[81]  R. Müller,et al.  Semisolid SLN dispersions for topical application: influence of formulation and production parameters on viscoelastic properties. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[82]  Robert Gurny,et al.  Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. , 2002, International journal of pharmaceutics.

[83]  R. Müller,et al.  Lipid-Drug-Conjugate (LDC) Nanoparticles as Novel Carrier System for the Hydrophilic Antitrypanosomal Drug Diminazenediaceturate , 2002, Journal of drug targeting.

[84]  R. Cavalli,et al.  Intravenous Administration to Rabbits of Non-stealth and Stealth Doxorubicin-loaded Solid Lipid Nanoparticles at Increasing Concentrations of Stealth Agent: Pharmacokinetics and Distribution of Doxorubicin in Brain and Other Tissues , 2002, Journal of drug targeting.

[85]  D D Allen,et al.  Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier , 2002, Drug development and industrial pharmacy.

[86]  Qiang Zhang,et al.  In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. , 2001, Chemical & pharmaceutical bulletin.

[87]  R. Müller,et al.  Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. , 2001, International journal of pharmaceutics.

[88]  R. Cavalli,et al.  Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II--tissue distribution. , 2001, Pharmacological research.

[89]  K. Mäder,et al.  Solid lipid nanoparticles: production, characterization and applications. , 2001, Advanced drug delivery reviews.

[90]  H. van de Waterbeemd,et al.  Property-based design: optimization of drug absorption and pharmacokinetics. , 2001, Journal of medicinal chemistry.

[91]  J. Kreuter,et al.  Nanoparticulate systems for brain delivery of drugs. , 2001, Advanced drug delivery reviews.

[92]  R. Müller,et al.  The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. , 2001, International journal of pharmaceutics.

[93]  R. Cavalli,et al.  Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. , 2000, Pharmacological research.

[94]  R. Cavalli,et al.  Biodistribution of Stealth and Non‐stealth Solid Lipid Nanospheres after Intravenous Administration to Rats , 2000, The Journal of pharmacy and pharmacology.

[95]  R. Müller,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[96]  R. Cavalli,et al.  Preparation and characterization of solid lipid nanospheres containing paclitaxel. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[97]  C. Mayer,et al.  Solid State NMR Investigations on Nanosized Carrier Systems , 2000, Pharmaceutical Research.

[98]  S. Gohla,et al.  Comparison of wax and glyceride solid lipid nanoparticles (SLN). , 2000, International journal of pharmaceutics.

[99]  R. Müller,et al.  Investigation on the viscoelastic properties of lipid based colloidal drug carriers. , 2000, International journal of pharmaceutics.

[100]  R. Müller,et al.  Influence of high pressure homogenisation equipment on nanodispersions characteristics. , 2000, International journal of pharmaceutics.

[101]  L. Fenart,et al.  Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. , 1999, The Journal of pharmacology and experimental therapeutics.

[102]  R. Cavalli,et al.  Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). , 1999, Pharmacological research.

[103]  Jia-bi Zhu,et al.  Body Distribution of Camptothecin Solid Lipid Nanoparticles After Oral Administration , 1999, Pharmaceutical Research.

[104]  R. Müller,et al.  Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. , 1999, International journal of pharmaceutics.

[105]  P. Dore‐Duffy,et al.  Role of central nervous system microvascular pericytes in activation of antigen‐primed splenic T‐lymphocytes , 1999, Journal of neuroscience research.

[106]  R. Müller,et al.  Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[107]  W Mehnert,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. , 1999, Journal of microencapsulation.

[108]  Rainer H. Müller,et al.  Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN) dispersions , 1998 .

[109]  B. Sabel,et al.  Sterilization of unloaded polybutylcyanoacrylate nanoparticles , 1998 .

[110]  W Mehnert,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery--drug release and release mechanism. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[111]  N. Phillips,et al.  Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization. , 1998, Journal of microencapsulation.

[112]  H. Bunjes,et al.  Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential , 1997 .

[113]  K. Westesen,et al.  Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles , 1997 .

[114]  M. Trotta,et al.  Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles , 1997 .

[115]  D. A. Kharkevich,et al.  Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles , 1997, Pharmaceutical Research.

[116]  Y. Sai,et al.  Blood‐brain‐barrier Transport of Lipid Microspheres Containing Clinprost, a Prostaglandin I2 Analogue , 1996, The Journal of pharmacy and pharmacology.

[117]  D. Begley,et al.  The Blood‐brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System , 1996, The Journal of pharmacy and pharmacology.

[118]  H. Bunjes,et al.  Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix , 1995 .

[119]  M. Fresta,et al.  Liposomes as In‐vivo Carriers for Citicoline: Effects on Rat Cerebral Post‐ischaemic Reperfusion # , 1994, The Journal of pharmacy and pharmacology.

[120]  K. Westesen,et al.  Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles , 1994 .

[121]  V. Hruby,et al.  Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[122]  D. Chen,et al.  Biodistribution of calcitonin encapsulated in liposomes in mice with particular reference to the central nervous system. , 1993, Biochimica et biophysica acta.

[123]  W. Pardridge,et al.  Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[124]  A. Florence,et al.  The effect of non‐ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice , 1985, The Journal of pharmacy and pharmacology.

[125]  P. Couvreur,et al.  Toxicity of polyalkylcyanoacrylate nanoparticles I: Free nanoparticles. , 1982, Journal of pharmaceutical sciences.

[126]  P. Couvreur,et al.  Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles. , 1982, Journal of pharmaceutical sciences.

[127]  V A Levin,et al.  Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.

[128]  P. Diwan,et al.  Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[129]  F. Lauretani,et al.  Parkinson's disease (PD) in the elderly: an example of geriatric syndrome (GS)? , 2012, Archives of gerontology and geriatrics.

[130]  W. Pardridge,et al.  Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. , 2012, Methods in enzymology.

[131]  R. Müller,et al.  Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. , 2010, Handbook of experimental pharmacology.

[132]  G. Giammona,et al.  Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. , 2010, Nanomedicine.

[133]  E. Barbu,et al.  The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. , 2009, Expert opinion on drug delivery.

[134]  J. Bruce,et al.  Targeting the brain: rationalizing the novel methods of drug delivery to the central nervous system. , 2007, Neurocritical care.

[135]  Rainer H Müller,et al.  Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[136]  P. Bummer,et al.  Physical chemical considerations of lipid-based oral drug delivery--solid lipid nanoparticles. , 2004, Critical reviews in therapeutic drug carrier systems.

[137]  V. Venkateswarlu,et al.  Novel delivery systems for drug targeting to the brain , 2004 .

[138]  C. Barbosab,et al.  Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery , 2004 .

[139]  D. Begley,et al.  Structural and functional aspects of the blood-brain barrier. , 2003, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[140]  W. Pardridge.  Targeting neurotherapeutic agents through the blood-brain barrier. , 2002, Archives of neurology.

[141]  Qiang Zhang,et al.  [In vitro and in vivo study of two kinds of long-circulating solid lipid nanoparticles containing paclitaxel]. , 2002, Yao xue xue bao = Acta pharmaceutica Sinica.

[142]  W. Pardridge.  Why is the global CNS pharmaceutical market so under-penetrated? , 2002, Drug discovery today.

[143]  S. Gohla,et al.  Scaling up feasibility of the production of solid lipid nanoparticles (SLN). , 2001, Die Pharmazie.

[144]  D. A. Kharkevich,et al.  Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. , 1998, Journal of microencapsulation.

[145]  V. Masson,et al.  Influence of sterilization processes on poly(epsilon-caprolactone) nanospheres. , 1997, Biomaterials.

[146]  V. Masson,et al.  Influence of sterilization processes on poly(ε-caprolactone) nanospheres , 1997 .

[147]  R. Müller,et al.  Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. , 1996, Journal of drug targeting.

[148]  J. E. Diederichs,et al.  Liposome in Kosmetika und Arzneimitteln , 1994 .